FacebookTwitterGoogle+RedditEmail

Big Pharma Fights Proposal to Keep It From Looting Medicare

Photo by ProgressOhio | CC BY 2.0

The Trump administration has proposed that insurance plans providing drug coverage to Medicare beneficiaries will no longer be forced to cover six hitherto “protected” drug classes. The classes––which include drugs for psychiatric conditions, cancer and immune diseases––are among the priciest of all drugs and account for as much as 33 percent of total outpatient drug spending under Part D of Medicare.

Under the proposal, Medicare plans could “exclude from their formularies protected class drugs with price increases that are greater than inflation, as well as certain new drug formulations that are not a significant innovation over the original product,” says Seema Verma, the administrator of the Centers for Medicare and Medicaid Services.

In 2014, the Obama administration sought the same “price relief” for Medicare but was defeated by drug industry lobbyists. At the time, 100 pills of the “protected” psychiatric drug Abilify cost $1,644, 100 pills of the “protected” psych drug Geodon cost $958, 100 pills of the “protected” psychiatric drug Invega cost $1,789 and 100 pills of the “protected” psych drug Seroquel cost $2,000. Since then, even pricier psychiatric drugs have emerged as well as 6-digit cancer drugs.

The Obama proposal was roundly defeated by drug industry funded groups like the National Alliance on Mental Illness (NAMI). NAMI received $23 million in just two years from drug makers and is heavily financed by them.

The proposal “undermines a key protection for some of the sickest, most vulnerable Medic beneficiaries,” said NAMI lobbyist Andrew Sperling, one of many voices that defeated the proposal. “You get much better outcomes when a doctor can work with patients to figure out which medications will work best.” He might have added, as long as the taxpayer pays.

Such drug industry tactics are well known. “When insurers balk at reimbursing patients for new prescription medications, these groups typically swing into action, rallying sufferers to appear before public and consumer panels, contact lawmakers, and provide media outlets a human face to attach to a cause,” writes Melissa Healy of the Los Angeles Times about this well known Pharma tactic to loot Medicare dollars.

The six protected drug classes are not the only example of lobbyist-initiated regulations which protect nothing more than drug industry profits and its expensive psychiatric drugs, many of which have cheaper alternatives. In Texas, a Medicaid “decision tree” called the Texas Medical Algorithm Project was instituted that literally requires doctors to prescribe the newest psychiatric drugs first. It was, not surprisingly, funded by the Johnson & Johnson linked Robert Wood Johnson Foundation.

Already drug industry lobbyists are berating the new Trump Medicare proposal on behalf of the “sickest, most vulnerable Medicare beneficiaries” who they say will be hurt if taxpayers won’t fund its 4 and 5 digit priced drugs. The Pharma-friendly Alliance for Patient Access has saturated broadcast airwaves warning cancer patients about “European style” restrictions on the “newest drugs” without which they will presumably die. The scare tactic ads even give out lawmakers’ phone numbers for patients to call.

Yet few to none of the newer psychiatric or cancer drugs show clear improvements over cheaper ones. They all lack the safety profiles of older drugs that are widely in use and their main benefit is enriching Pharma.

Will this cost-saving Medicare proposal be defeated as it was in 2014?

 

 

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

January 24, 2019
Karen J. Greenberg
Creating a Global Lost Generation
Jesse Jackson
America Has Lost Its Common Sense
Noa Mendelsohn Aviv
Rebranding Canada’s Solitary Confinement Policy Doesn’t Change What It Is
Ramzy Baroud
False ‘Victories’: Is the PA Using the ‘State of Palestine’ to Remain in Power?
Binoy Kampmark
Eyeing the White House: the Democratic Field
Russell Mokhiber
Single Payer Gold Standard HR 676 Rest in Peace
David Swanson
The World Will End in Fire
David Macaray
Celebrity Bullshit
Dean Baker
How Worried Should We be If China’s Growth Rate Slows to 6.4%?
Wim Laven
What Makes America Great?
January 23, 2019
Paul Street
Time for the U.S. Yellow Vests
Charles McKelvey
Popular Democracy in Cuba
Kenn Orphan
The Smile of Class Privilege
Leonard Peltier
The History Behind Nate Phillips’ Song
Kenneth Surin
Stalled Brexit Goings On
Jeff Cohen
The System’s Falling Apart: Were the Dogmatic Marxists Right After All?
Cira Pascual Marquina
Chavez and the Continent of Politics: a Conversation with Chris Gilbert
George Ochenski
Turning Federal Lands Over to the States and Other Rightwing Fantasies
George Wuerthner
Forest Service Ignores Science to Justify Logging
Raouf Halaby
In the Fray: Responses to Covington Catholic High
Kim C. Domenico
No Saviors But Ourselves; No Disobedience Without Deeper Loyalty
Ted Rall
Jury Trial? You Have No Right!
Michael Doliner
The Pros and Cons of Near Term Human Extinction
Lee Ballinger
Musical Unity
Elliot Sperber
The Ark Builders
January 22, 2019
Patrick Cockburn
On the Brink of Brexit: the Only Thing Most People Outside Westminster Know About Brexit is That It’s a Mess
Raouf Halaby
The Little Brett Kavanaughs from Covington Catholic High
Dean Baker
The Trump Tax Cut is Even Worse Than They Say
Stanley L. Cohen
The Brazen Detention of Marzieh Hashemi, America’s Newest Political Prisoner
Karl Grossman
Darth Trump: From Space Force to Star Wars
Glenn Sacks
Teachers Strike Dispatch #8: New Independent Study Confirms LAUSD Has the Money to Meet UTLA’s Demands
Haydar Khan
The Double Bind of Human Senescence
Alvaro Huerta
Mr. President, We Don’t Need Your Stinking Wall
Howard Lisnoff
Another Slugger from Louisville: Muhammad Ali
Nicole Patrice Hill – Kollibri terre Sonnenblume
The Scarlet “I”: Climate Change, “Invasive” Plants and Our Culture of Domination
Jonah Raskin
Disposable Man Gets His Balls Back
Thomas Knapp
Now More Than Ever, It’s Clear the FBI Must Go
January 21, 2019
W. T. Whitney
New US Economic Attack Against Cuba, Long Threatened, May Hit Soon
Jérôme Duval
Macronist Repression Against the People in Yellow Vests
Dean Baker
The Next Recession: What It Could Look Like
Eric Mann
All Hail the Revolutionary King: Martin Luther King and the Black Revolutionary Tradition
Binoy Kampmark
Spy Theories and the White House: Donald Trump as Russian Agent
Edward Curtin
We Need a Martin Luther King Day of Truth
Bill Fried
Jeff Sessions and the Federalists
Ed Corcoran
Central America Needs a Marshall Plan
FacebookTwitterGoogle+RedditEmail